Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity.
Glesby
Marshall J
MJ
Gerber
John G
JG
D000140:Acidosis, Lactic / Q000139:chemically induced*; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000378:metabolism; D000998:Antiviral Agents / Q000009:adverse effects*; D004272:DNA, Mitochondrial / Q000187:drug effects*; D016049:Didanosine / Q000009:adverse effects* / Q000378:metabolism; D004357:Drug Synergism; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D008657:Metabolic Clearance Rate; D010195:Pancreatitis / Q000139:chemically induced*; D012254:Ribavirin / Q000009:adverse effects*
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D004272:DNA, Mitochondrial; D012254:Ribavirin; D016049:Didanosine